En vivo

Clinical OMICsExposure to Moderate Air Pollution Raises Cardiovascular Disease Risk Endpoints NewsEli Lilly's claims data deadline may kick off new 340B fight Clinical OMICsFirst Phase III for Resected CRC ctDNA-Guided Therapy Shows Mixed Results AgilentAgilent Showcases Integrated Mass Spectrometry and Chromatography Solutions at ASMS 2026 - the-scientist.com Endpoints NewsGrace Science says FDA bottleneck jeopardizes rare disease therapy Clinical OMICsDigital Pathology and the NHS: Overcoming Barriers to a More Connected Future FierceBiotechFueled by M&A and partnerships, biotech is poised for continued growth: EY FierceBiotechGalmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market BioPharma DiveMerck, Gilead report mixed outcomes in key lung cancer, HIV studies Endpoints NewsA different approach to lowering healthcare costs CellmRNA 3′ UTRs chaperone intrinsically disordered regions to control protein activity Clinical OMICsDiabetes Drug Linked to Reduced Heart Failure in High-Risk Gene Carriers

Clinical OMICs 9 jun 2026

Beyond the Genome: Five Emerging Leaders in Epigenetics Diagnostics

Epigenetics is increasingly powering cancer diagnostics and liquid biopsies. These emerging private companies are spurring the market with structural DNA, fragm...

Epigenetics is increasingly powering cancer diagnostics and liquid biopsies. These emerging private companies are spurring the market with structural DNA, fragmentomics, and DNA methylation tests. Our understanding of the role of epigenetics in disease is growing rapidly, driven by rapid advances in sequencing technology and computing. Epigenetic processes such as DNA methylation, histone modifications, and […] The post Beyond the Genome: Five Emerging Leaders in Epigenetics Diagnostics appeared first on Inside Precision Medicine .